Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (Part Two).
This part of our study presents results of laboratory evaluations in patients with BPH during treatment with prazosin and doxazosin. After 72 weeks serum PSA and PAP fell by 40.2% and 82%, respectively. Blood urea nitrogen concentration decreased by 28.5% and serum creatinine by 20.8%. The results confirm long-term favourable effects of the therapy of patients with BPH.
Dutkiewicz
S
S
Department of Urology, Ministry of Internal Affairs Central Clinical Hospital, Warsaw, Poland.
Witeska
A
A
Stepień
K
K
D000135:Acid Phosphatase / Q000097:blood; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D017292:Doxazosin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011224:Prazosin / Q000627:therapeutic use; D011467:Prostate; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; D003404:Creatinine; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen; D017292:Doxazosin; D011224:Prazosin